Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene

18.12.2007
The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth. Prior to this report, there were conflicting opinions about whether that was the case, say Mayo Clinic investigators who presented their findings at the San Antonio Breast Cancer Symposium.

The analysis came from the North Central Cancer Treatment Group's clinical trial N9831 which tested the use of Herceptin in combination with chemotherapy in patients with surgically-removed HER2+, early-stage, node-positive or high-risk, node-negative breast cancer. Data from the trial on the long term efficacy and safety of this treatment were presented recently by Mayo Clinic researchers and collaborators as part of a joint analysis with another U.S. trial. They demonstrated the significant benefit of using Herceptin, which is a monoclonal antibody that binds the HER2 protein, shutting down its function.

HER2+ breast cancer accounts for approximately 20 percent of all breast cancer cases, and most oncologists decide whether to use Herceptin based on a test that measures the amount of HER2 protein or the number of extra ("amplified") genes in a patient's tumor tissue sample. The goal of this sub-study was to see if patients with more than two chromosome 17s (known as polysomy 17) had a different outcome from use of Herceptin.

"Some oncologists thought that patients with non-amplified HER2 gene in polysomy 17 tumors may respond to Herceptin because they may have that many extra HER2 genes resulting in HER2 protein over expression. Others thought they might not benefit because they had far too many HER2 genes from the extra chromosomes, producing too much HER2 protein, which may overwhelm Herceptin's effectiveness," says the study's lead investigator, Monica M. Reinholz, Ph.D., an assistant professor at Mayo Clinic's campus in Rochester, Minn. "No one knew if they would respond, in general, or not."

The research team, led by Edith A. Perez, M.D., from the Mayo Clinic campus in Jacksonville, Fla., specifically found that 865 patients had HER2 gene amplified tumors with polysomy 17 and 685 women had amplification with two copies (normal) of chromosome 17 did equally well using Herceptin. Their disease-free survival was about 89 percent three years after treatment and between 88 percent and 89 percent five years after therapy, Dr. Reinholz says. "These results of this new analysis suggest that chromosome 17 number status is not predictive of Herceptin response in patients with HER2 amplified tumors," she says.

Also, they found that women with HER2 gene amplification and polysomy 17 who were treated only with chemotherapy seemed to have had a better outcome than patients treated with chemotherapy who did not have the extra chromosomes. Three-year disease-free survival was 83 percent and 75 percent, respectively, and five-year disease-free survival was 78 percent and 68 percent. "This is an interesting and unexpected finding," Dr. Reinholz says.

Researchers also found that 37 patients had HER2 non-amplified and polysomy 17 tumors, and 67 patients had HER2 non-amplified and normal chromosome 17 tumors. There was no apparent influence of polysomy 17 in predicting Herceptin benefit in women with HER2 non-amplified tumors, they say. However, due to the small number of cases in this study, additional patients will be needed to determine whether Herceptin is beneficial in patients with non-amplified HER2 tumors, the researchers say.

The study was funded by Genentech and the Breast Cancer Research Foundation.

Paul Scotti | EurekAlert!
Further information:
http://www.mayoclinic.org/news

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

Study shows how water could have flowed on 'cold and icy' ancient Mars

18.10.2017 | Physics and Astronomy

Navigational view of the brain thanks to powerful X-rays

18.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>